HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.
Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O, Briney B, Schiffner T, Garces F, Freund NT, Gitlin AD, Menis S, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan AA, Yun DS, Mayer CT, Ward AB, Burton DR, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WR. · 2016
Read HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. by Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O, Briney B, Schiffner T, Garces F, Freund NT, Gitlin AD, Menis S, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan AA, Yun DS, Mayer CT, Ward AB, Burton DR, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WR. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5040827.txt.
Introduction
Jon M. Steichen and a large co-author group design HIV vaccine parts in Immunity in 2016. The most common protective antibodies found in infected people aim at a sugar-coated site, called the N332 supersite, on the virus's envelope spike. Natural spike proteins cannot grip the starter forms of those antibodies, so they cannot launch the response. The team used a cell display method to breed spike variants that can.
Their stabilized trimers kept a near-native shape while gaining grip on the starter antibodies of the PGT121 family. Packed on fat bubbles, the trimers woke the right starter B cells in dishes, and in mice carrying the starter gene they primed matching early responses. Steps between natural spike and designed one form a ladder: a shot series starting with the designed primer and climbing toward the native spike. The same design logic could serve other hard targets.
Catalog record
| CREATOR | Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O, Briney B, Schiffner T, Garces F, Freund NT, Gitlin AD, Menis S, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan AA, Yun DS, Mayer CT, Ward AB, Burton DR, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WR. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies By Jon M Steichen, Daniel W Kulp, Talar Tokatlian, Amelia Escolano, Pia Dosenovic, Robyn L Stanfield, Laura E McCoy, Gabriel Ozorowski, Xiaozhen Hu, Oleksandr Kalyuzhniy, Bryan Briney, Torben Schiffner Published in: Immunity DOI: 10.1016/j.immuni.2016.08.016 ABSTRACT Summary Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) trimer are the most common bnAbs induced during infection, making them promising leads for vaccine design. Wild-type Env glycoproteins lack detectable affinity for supersite-bnAb germline precursors and are therefore unsuitable immunogens to prime supersite-bnAb responses. We employed mammalian cell surface display to design stabilized Env trimers with affinity for germline-reverted precursors of PGT121-class supersite bnAbs. The trimers maintained native-like antigenicity and structure, activated PGT121 inferred-germline B cells ex vivo when multimerized on liposomes, and primed PGT121-like responses in PGT121 inferred-germline knockin mice. Design intermediates have levels of epitope modification between wild-type and germline-targeting trimers; their mutation gradient suggests sequential immunization to induce bnAbs, in which the germline-targeting prime is followed by progressively less-mutated design intermediates and, lastly, with native trimers. The vaccine design strategies described could be utilized to target other epitopes on HIV or other pathogens. INTRODUCTION A vaccine is needed for global HIV prevention. Broadly neutralizing antibodies (bnAbs) directed against relatively conserved epitopes in the otherwise highly antigenically variable HIV envelope (Env) glycoprotein trimer offer important guides for vaccine design. BnAbs have been isolated from a small minority of HIV-infected individuals and have been shown to protect against challenge in various animal models, but have not been induced by vaccination in humans or standard animal models (Burton and Hangartner, 2016, Mascola and Haynes, 2013, West et al., 2014). BnAbs recovered from natural infection are typically highly mutated (Klein et al., 2013a, Mouquet et al., 2010, Pancera et al., 2010, Scheid et al., 2009, Walker et al., 2011, Xiao et al., 2009, Zhou et al., 2010) and many also contain insertions and/or deletions (Kepler et al., 2014), owing to chronic stimulation of B cells by mutating Env. Many bnAbs also possess unusually long or short heavy-chain complementarity determining region 3 (CDR3) loops (Scheid et al., 2011, Walker et al., 2009, Walker et al., 2011, Wu et al., 2011, Zhou et al., 2010) and some are polyreactive (Haynes et al., 2005). Less mutated bnAbs with fewer unusual features have been engineered, offering more tractable goals for consistent vaccine elicitation (Georgiev et al., 2014, Jardine et al., 2016b, Sok et al., 2013). Overall, bnAb elicitation by vaccination presents a major challenge. Recombinant native-like trimers are promising HIV vaccine components because they contain the conformational epitopes of most known bnAbs and lack many non-neutralizing epitopes present on less native constructs (Julien et al., 2013, Kong et al., 2016, Kwon et al., 2015, Lyumkis et al., 2013, Pancera et al., 2014, Sanders et al., 2013, Scharf et al., 2015). However, native-like trimers have features that might impede bnAb induction; they are highly glycosylated and expose both strain-specific neutralizing epitopes and non-neutralizing epitopes. Immunization with native-like trimers in standard mouse, rabbit, and macaque models has thus far elicited either non-neutralizing antibodies (Hu et al., 2015) or neutralizing antibodies only against the immunogen strain (de Taeye et al., 2016, Sanders et al., 2015) analogous to the strain-specific responses to the seasonal flu vaccine in humans. Induction of HIV bnAbs will likely require development of vaccination strategies that focus responses to relatively conserved, sub-dominant epitopes and avoid or suppress responses to non-neutralizing and strain-specific epitopes. Germline targeting, a vaccine priming strategy to initiate the affinity maturation of specific germline-precursor B cells, could help solve this immunofocusing problem by preferentially activating bnAb precursors (Dimitrov, 2010, Xiao et al., 2009). The strategy aims to activate bnAb-precursor B cells, select productive (bnAb-like) somatic mutations, and produce memory B cells that can be boosted subsequently to select additional productive mutations (Dosenovic et al., 2015, Jardine et al., 2015). For some bnAbs, inferred precursors have affinity for Env from particular HIV isolates (Andrabi et al., 2015, Doria-Rose et al., 2014, Gorman et al., 2016, Liao et al., 2013), facilitating design of priming immunogens based on Env from those isolates (Haynes et al., 2012). For other bnAbs, efforts to identify wild-type (WT) Env that bind inferred precursors have failed (Hoot et al., 2013, Jardine et al., 2013, McGuire et al., 2013, Scheid et al., 2011, Xiao et al., 2009, Zhou et al., 2010). These latter cases require design of modified Env to serve as a priming immunogen (Dimitrov, 2010, Pancera et al., 2010, Xiao et al., 2009, Zhou et al., 2010). Proof of principle that designed germline-targeting immunogens can activate their intended precursors and generate a potentially boostable memory response was recently demonstrated in knockin mice with B cell precursors for VRC01-class bnAbs directed to the CD4-binding site (Dosenovic et al., 2015, Jardine et al., 2015, McGuire et al., 2016). After a germline-targeting prime, induction of bnAbs is expected to require a succession of boosts, driving a succession of germinal-center reactions, in order to select sufficient mutations (Dimitrov, 2010, Dosenovic et al., 2015, Haynes et al., 2012, Jardine et al., 2013, Jardine et al., 2015, Jardine et al., 2016b, Klein et al., 2013b, Liao et al., 2013, McGuire et al., 2013, McGuire et al., 2016, Pancera et al., 2010, Wu et al., 2011, Xiao et al., 2009, Zhou et al., 2010). Supporting the concept that sequential immunization with different immunogens will be required to develop a bnAb response, native-like trimers but not germline-targeting immunogens were found to boost near-bnAb B cells (bearing a mature VRC01-class bnAb heavy chain) to induce cross-neutralizing Abs (Dosenovic et al., 2015). Glycan-dependent bnAbs in general, and N332-supersite bnAbs in particular, are important targets for germline-targeting vaccine design. In a recent longitudinal study of HIV infection in Africa, more than half of the HIV-infected individuals who produced bnAb responses produced them against glycan-directed epitopes, the majority of which were within the N332 supersite (Landais et al., 2016). The prevalence of N332-supersite bnAb responses is probably due in part to the high accessibility of their epitopes on top of the trimer. Among N332-supersite bnAbs, PGT121-class bnAbs have been particularly well characterized, providing strong rationale for germline-targeting efforts. PGT121-class bnAbs are among the most potent bnAbs (Mouquet et al., 2012, Walker et al., 2011), and PGT121 delivered passively to macaques protects against SHIV (simian-human immunodeficiency virus) infection (Moldt et al., 2012, Shingai et al., 2014) and can suppress viremia when delivered after infection (Barouch et al., 2013, Shingai et al., 2013). However, PGT121-class inferred precursors show no measureable affinity for WT Env proteins that have been evaluated (Mouquet et al., 2012, Sok et al., 2013). Thus, development of a priming immunogen for PGT121-class precursors requires either design of a modified Env or identification of a natural Env with PGT121-class germline-binding capacity. Crystal structures have been determined for several PGT121-class bnAbs in complex with either BG505 SOSIP native-like trimers or gp120 (Garces et al., 2015, Garces et al., 2014, Julien et al., 2013, Kong et al., 2016, Pancera et al., 2014) and for unliganded structures of two germline-reverted PGT121 variants (Mouquet et al., 2012, Sok et al., 2013), providing critical information to guide design of modified Env for PGT121-class germline